# US 2025/0027954 A1 · Methods of detecting and treating cerebral aneurysms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0027954 A1
- Document ID: US20250027954A1
- Status: Published application
- Kind: A1
- Application number: 18/792,908
- Filed: 2024-08-02
- Published: 2025-01-23
- Earliest claimed: 2022-02-04
- Assignees: University Pf Pittsburgh - of the Commonwealth System of Higher Eduction; Upmc
- Applicants: University of Pittsburgh-of the Commonwealth System of Higher Education; Upmc
- Inventors: Robert Max Friedlander; Ali A. Alattar; Kamil W. Nowicki; Michael M. McDowell; Aditya M. Mittal
- Web page: https://patentgrep.com/patent/US20250027954A1

## CPC

- G01N 30/88: Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K 16/24: against cytokines, lymphokines or interferons
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G01N 30/72: Mass spectrometers {(mass spectrometers per se H01J49/00)}
- G01N 2030/8813: {biological materials}
- G01N 2333/521: Chemokines
- G01N 2333/5446: IL-16
- G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- G01N 2800/329: Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present disclosure provides a whole blood, protein-based diagnostic test for presence of unruptured aneurysms and allow for tracking progression of unruptured, ruptured, and previously treated aneurysms to guide clinical decision making. Further, the present disclosure relates to methods of treating aneurysms.

## Claims

### Claim 1

A method of treating an aneurysm in a subject in need thereof, comprising
a) measuring, in a biological sample of the subject, an expression level of (i) I-309, IL-16, IL-1 alpha, MCP-2, MIP-1 delta, and/or uPAR, (ii) I-309, IL-16, MCP-4, MIP-1 delta, CXCL7/NAP-2 and/or uPAR, or (iii) FasL and/or CCL22;
b) identifying the subject as having an aneurysm if the expression level of (i) I-309, IL-16, IL-1 alpha, MCP-2, MIP-1 delta, and/or uPAR, (ii) I-309, IL-16, MCP-4, MIP-1 delta, CXCL7/NAP-2 and/or uPAR, or (iii) FasL and/or CCL22 is increased relative to a first reference sample; and
c) administering an effective amount of an aneurysm inhibitor to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the aneurysm inhibitor is a platelet inhibitor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the platelet inhibitor is selected from the group consisting of a glycoprotein IIB/IIIA inhibitor, a CXCL7 inhibitor, a CXCR1/2 inhibitor, and a combination thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the glycoprotein IIB/IIIA inhibitor is clopidogrel, a salt thereof, or a derivative thereof.

### Claim 5 (depends on 3)

The method of claim 3, wherein the CXCL7 inhibitor is an antibody anti-CXCL7.

### Claim 6 (depends on 3)

The method of claim 3, wherein the CXCR1/2 inhibitor is reparixin, a salt thereof, or a derivative thereof.

### Claim 7 (depends on 1)

The method of claim 1, further comprising administering a therapeutically effective amount of a secondary aneurysm inhibitor.

### Claim 8

A method for preventing or reducing the risk of growth and/or rupture of an aneurysm in a subject in need thereof, comprising:
a) measuring, in a biological sample of the subject, an expression level of (i) I-309, IL-16, IL-1 alpha, MCP-2, MIP-1 delta, and/or uPAR, (ii) I-309, IL-16, MCP-4, MIP-1 delta, CXCL7/NAP-2 and/or uPAR, or (iii) FasL and/or CCL22;
b) identifying the subject as having an aneurysm if the expression level of (i) I-309, IL-16, IL-1 alpha, MCP-2, MIP-1 delta, and/or uPAR, (ii) I-309, IL-16, MCP-4, MIP-1 delta, CXCL7/NAP-2 and/or uPAR, or (iii) FasL and/or CCL22 is increased relative to a first reference sample;
c) measuring, in the biological sample, an expression level of one or more cytokines;
d) determining whether the subject has or is at risk of rupture of the aneurysm; and
e) administering a therapeutically effective amount of an aneurysm inhibitor to the subject.

### Claim 9 (depends on 1)

The method of claim 1, wherein the one or more cytokines are selected from the group consisting of RANTES, IL-12 p40/p70, MIP-1α, sTNF.RI, MCP-1, MCP-2, MCP-3, MIG, IL-1ra, IL1-α, or a combination thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein
a) a reduced expression level of RANTES relative to a second reference sample indicates that the subject has or is at risk of rupture of the aneurysm;
b) a reduced expression level of IL-12 p40/p70 relative to the second reference sample indicates that the subject has or is at risk of rupture of the aneurysm;
c) a reduced expression level of MIP-1α relative to the second reference sample indicates that the subject has or is at risk of rupture of the aneurysm;
d) a reduced expression level of sTNF.RI relative to the second reference sample indicates that the subject has or is at risk of rupture of the aneurysm;
e) an increased expression level of MCP-1 relative to the second reference sample indicates that the subject has or is at risk of rupture of the aneurysm;
I) an increased expression level of MCP-2 relative to the second reference sample indicates that the subject has or is at risk of rupture of the aneurysm;
g) an increased expression level of MCP-3 relative to the second reference sample indicates that the subject has or is at risk of rupture of the aneurysm;
h) an increased expression level of MIG relative to the second reference sample indicates that the subject has or is at risk of rupture of the aneurysm;
i) an increased expression level of IL-1ra relative to the second reference sample indicates that the subject has or is at risk of rupture of the aneurysm; and/or
j) an increased expression level of IL1-α relative to the second reference sample indicates that the subject has or is at risk of rupture of the aneurysm.

### Claim 11 (depends on 1)

The method of claim 1, wherein the aneurysm is a cerebral aneurysm.

### Claim 12 (depends on 1)

The method of claim 1, wherein the biological sample is a blood sample, a serum sample, a plasma sample, or a cerebrospinal fluid sample.

### Claim 13 (depends on 1)

The method of claim 1, wherein the biological sample is a blood sample.

### Claim 14 (depends on 1)

The method of claim 1 further comprising monitoring the subject's responsiveness to an anti-aneurysm treatment, comprising:
a) measuring, in the biological sample, an expression level of one or more cytokines; and
b) determining whether the subject is responsive to the anti-aneurysm treatment;
wherein the subject is administered or has been administered with the anti-aneurysm treatment.

### Claim 15

A method of identifying a subject having or at risk of developing an aneurysm by one or more computing systems, comprising:
receiving, from a client device via a user interface of a software executing on the client device, one or more inputs associated with the subject;
determining, based on one or more models, one or more measures regarding aneurysm presence and aneurysm rupture, wherein the one or more measures comprise one or more of a first probability of the subject harboring an aneurysm, a second probability of an ruptured aneurysm in the subject, or a third probability of an aneurysm with impending rupture in the subject; and
sending, to the client device via the user interface, instructions for presenting the one or more determined measures regarding aneurysm presence and aneurysm rupture.

### Claim 16 (depends on 15)

The method of claim 15, wherein the one or more inputs comprise one or more of demographic information, a co-morbidity, an aneurysm size, an aneurysm location, or a cytokine.

### Claim 17 (depends on 15)

The method of claim 15, wherein the one or more inputs comprise:
a) one or more cytokines selected from the group consisting of I-309, IL-16, IL-1 alpha, MCP-2, MIP-1 delta, uPAR or a combination thereof;
b) one or more cytokines selected from the group consisting of I-309, IL-16, MCP-4, MIP-1 delta, CXCL7/NAP-2, uPAR, or a combination thereof;
c) one or more cytokines selected from the group consisting of FasL, CCL22, or a combination thereof; or
d) one or more cytokines selected from the group consisting of RANTES, IL-12 p40/p70, MIP-1α, sTNF.RI, MCP-1, MCP-2, MCP-3, MIG, IL-1ra, IL1-α, or a combination thereof.

### Claim 18 (depends on 15)

The method of claim 15, wherein the one or more models are generated based on one or more of retrospective human cytokine data or sample stratification based on t-SNE inflammatory cytokine analysis.

### Claim 19

One or more computer-readable non-transitory storage media embodying software that is operable when executed to:
receive, from a client device via a user interface of a software executing on the client device, one or more inputs associated with the subject;
determine, based on one or more models, one or more measures regarding aneurysm presence and aneurysm rupture, wherein the one or more measures comprise one or more of a first probability of the subject harboring an aneurysm, a second probability of an ruptured aneurysm in the subject, or a third probability of an aneurysm with impending rupture in the subject; and
send, to the client device via the user interface, instructions for presenting the one or more determined measures regarding aneurysm presence and aneurysm rupture.

### Claim 20

A system comprising: one or more processors; and a non-transitory memory coupled to the processors comprising instructions executable by the processors, the processors operable when executing the instructions to:
receive, from a client device via a user interface of a software executing on the client device, one or more inputs associated with the subject;
determine, based on one or more models, one or more measures regarding aneurysm presence and aneurysm rupture, wherein the one or more measures comprise one or more of a first probability of the subject harboring an aneurysm, a second probability of an ruptured aneurysm in the subject, or a third probability of an aneurysm with impending rupture in the subject; and
send, to the client device via the user interface, instructions for presenting the one or more determined measures regarding aneurysm presence and aneurysm rupture.
